Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 4 Years in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. J of Skin 2024, 8 (4), s407. https://doi.org/10.25251/skin.8.supp.407.